Drug Database
Back to search

Poland· PL-100342559

Sivextro

A tedizolid product containing tedizolidi phosphas, registered in Poland by Merck Sharp & Dohme B.V.. The same ATC class is registered in 14 of our 19 countries.

ATC J01XX11

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedSivextroATCJ01XX11REGISTER NO.PL-100342559PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about tedizolidi phosphasAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Tedizolid is registered in 14 of 19 countries.

Countries holding a registration under ATC J01XX11 (tedizolid), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 10 of them publish a price we can compare per daily dose
Search tedizolid products by name

Tedizolid · ATC J01XX11

14 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of tedizolid costs, country by country.

Normalised to the WHO defined daily dose (0.2 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Tedizolid · price per daily dose (0.2 g)

USD · FX 28 Sept 2026

  • IT Italy$346.95
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Tedizolidi phosphas
Manufacturer
Merck Sharp & Dohme B.V.
Country
Poland (PL)
ATC code
J01XX11
ATC class
Tedizolid
Defined daily dose
0.2 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05901549324952
  • gtin
    00191778013405

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

51 interactions on record for tedizolid.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check tedizolid against other medicinesHow interaction checks work

Tedizolid · interactions on record

51 records

  • 2 severe
  • 49 moderate

Most severe, free to view

  • OzanimodL04AA38severe
  • OzanimodL04AE02severe
  • Sodium picosulfateA06AB08moderate
  • SulfasalazineA07EC01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Tedizolid in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tedizolid products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Sivextro
  • Liechtenstein · Sivextro
  • Norway · Sivextro

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c6784317-d8ca-47fa-80c5-94691b5c5294
GET /v1/drugs/c6784317-d8ca-47fa-80c5-94691b5c5294?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "200 mg",
  "packaging": "05901549324952 ¦ Rp ¦ EU/1/15/991/001 ¦ 108013\n6 tabl.\n00191778013405 ¦ Rpz ¦ Skasowane ¦ EU/1/15/991/001 ¦ 127235\n6 tabl.",
  "substance": "Tedizolidii phosphas 200 mg",
  "common_name": "Tedizolidi phosphas",
  "pl_product_id": "100342559",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about tedizolid.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console